Pancreatic cancer is the fourth leading cause of cancer death among men and women in the US, and will result in an estimated 44,330 deaths in 2018.¹ The optimal multimodality therapy for resectable pancreatic ductal adenocarcinoma (PDAC) is controversial.² Several clinical trials support the use of adjuvant chemotherapy,^3–6 while other trials support the use of adjuvant chemoradiation.^7–10 Due to a lack of definitive data, current National Comprehensive Cancer Network (NCCN) guidelines recommend either adjuvant chemotherapy alone or adjuvant induction chemotherapy followed by chemoradiation with or without subsequent chemotherapy.¹¹ The adjuvant regimen that includes chemoradiation is recommended for patients with high-risk features, such as positive resection margins or positive lymph nodes.¹¹

中文翻译：

---

胰体或尾腺癌的辅助治疗：国家癌症数据库的一项研究

胰腺癌是美国男性和女性癌症死亡的第四大原因，预计 2018 年将导致 44,330 人死亡^。1可切除胰腺导管腺癌 (PDAC) 的最佳多模式治疗存在争议。²一些临床试验支持使用辅助化疗，^3-6而其他试验支持使用辅助放化疗。^7–10由于缺乏明确的数据，目前的国家综合癌症网络 (NCCN) 指南建议单独进行辅助化疗或辅助诱导化疗，然后进行放化疗，加或不加后续化疗。¹¹对于具有高风险特征（如切缘阳性或淋巴结阳性）的患者，建议使用包括放化疗在内的辅助方案。¹¹